Want to join the conversation?
$ABBV said it launched VENCLEXTA early in 2Q16 in its initial indication for relapsed/refractory CLL patients with a 17p deletion, which represents a smaller addressable patient population in the US. The company has begun a measured commercial rollout to ensure adequate physician training and expects a modest level of VENCLEXTA sales for 2016.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.